Preoperative Progressive Pneumoperitoneum and Botulinum Toxin Type A in Patients With Large Parastomal Hernia

Background: The combination of preoperative progressive pneumoperitoneum (PPP) and botulinum toxin type A (BTA) in adjuvant treatment of large parastomal hernia (LPH) has not been reported in the previous literature.Methods: From February 2018 to June 2019, 16 patients were diagnosed with LPH in our hospital were included in this study. All patients received PPP and BTA treatment to expand abdominal volume and extend abdominal muscle before surgery. The laparoscopic Sugarbaker method was preferred for defect close.Results: Before and after PPP and BTA, the mean volume of the parastomal hernia (VPH) was 1,522 and 1,644 cc, respectively (P < 0.01), and the mean volume of the abdominal cavity (VAC) was 5,847 and 9,408 cc, respectively (P < 0.01). The VPH/VAC ratio was decreased by an average of 8.4% after the combination management. And the lateral abdominal muscle length was increased by an average of 4.8 cm/side (P < 0.01). These patients underwent surgery successfully, and no hernia recurrence after (17.6 ± 2.4) months of follow-up.Conclusions: The combination of PPP and BTA effectively expand the abdominal volume, decrease the risk of abdominal compartment syndrome (ACS) postoperatively, and beneficial to laparoscopic repair of LPH.

Download Full-text

Clinical and electromyographic evaluation of botulinum toxin type A in the treatment of gummy smile: A prospective clinical study

Journal of Dental Research Dental Clinics Dental Prospects ◽

10.34172/joddd.2021.021 ◽

2021 ◽

Vol 15 (2) ◽

pp. 122-128

Author(s):

Payal Padmakar Mate ◽

Kumar Nilesh ◽

Anand Joshi ◽

Arun Panda

Keyword(s):

Botulinum Toxin ◽

Clinical Study ◽

Repeated Measures ◽

Botulinum Toxin Type A ◽

Type A ◽

Botulinum Toxin Type ◽

Prospective Clinical Study ◽

Upper Lip ◽

The Mean ◽

Gummy Smile

Background. The present study aimed to assess the effect of botulinum toxin type A (BTX-A) for the management of gummy smile and evaluate its stability after administrating BTX-A clinically and using electromyography. Methods. The investigators designed and implemented a prospective clinical study on 10 patients with a gummy smile. Patients with different types of gummy smile were injected with BTX-A in the levator muscles of the upper lip and were followed for six months. The effect of BTX-A was evaluated clinically and using electromyography preoperatively and after two weeks and three and six months. Statistical analyses were carried out using repeated measures ANOVA and post hoc Bonferroni tests for pairwise comparisons. Results. The sample consisted of 10 patients with an anterior gummy smile (n=3), posterior gummy smile (n=2), mixed gummy smile (n=3), and asymmetrical gummy smile (n=2). There were significant differences (P<0.001) between the mean gingival display and compound muscle action potential at two-weeks and three-month follow-ups. The maximum result was obtained at the two-week interval. The mean gingival display and C-MAP values increased slightly at the three-month postoperative interval and gradually increased to the baseline values at six-month follow-up. Conclusion. BTX-A is an effective, minimally invasive, and temporary treatment modality for gummy smiles. The electromyographic study is a convenient method for assessing changes in the upper lip muscle contractility to quantify the effect of BTX-A in the treatment of gummy smile.

Download Full-text

Preoperative progressive pneumoperitoneum and botulinum toxin type A in patients with large incisional hernia

Hernia ◽

10.1007/s10029-017-1582-2 ◽

2017 ◽

Vol 21 (2) ◽

pp. 233-243 ◽

Cited By ~ 44

Author(s):

J. Bueno-Lledó ◽

A. Torregrosa ◽

N. Ballester ◽

O. Carreño ◽

F. Carbonell ◽

...

Keyword(s):

Botulinum Toxin ◽

Incisional Hernia ◽

Botulinum Toxin Type A ◽

Type A ◽

Botulinum Toxin Type ◽

Large Incisional Hernia ◽

Preoperative Progressive Pneumoperitoneum

Download Full-text

Botulinum toxin type A wear-off phenomenon in chronic migraine patients: how long does the maximum efficiency last?

Arquivos de Neuro-Psiquiatria ◽

10.1590/0004-282x-anp-2020-0542 ◽

2021 ◽

Author(s):

Aygul Tantik PAK ◽

İsmet ÜSTÜN ◽

Yildizhan SENGUL

Keyword(s):

Botulinum Toxin ◽

Chronic Migraine ◽

Botulinum Toxin Type A ◽

Type A ◽

Botulinum Toxin Type ◽

Maximum Efficiency ◽

Neck Muscle ◽

The Third ◽

The Mean ◽

Monthly Change

ABSTRACT Background: Botulinum toxin Type A (BoNTA) is a successful treatment for chronic migraine prophylaxis. Objective: We aimed to evaluate the monthly change of effectiveness of BoNTA treatment. Methods: A total of 80 patients (70 females and 10 males) with chronic migraine were included. In our study protocol, we applied to 155 U across 31 fixed-sites and if the patient had pain, 40 U dose injections were applied across 8 specific head/neck muscle areas. Headache days and analgesic intake were noted before the BoNTA injection and during the interviews at the first, second, and third months after the BoNTA injection. Results: The mean age was 37.59 ± 7.60 and 87.5% of the patients were female. The mean number of headache days/month before BoNTA was 18.95±2.69, decreasing to 10.55±3.15 days/month in the first month (p<0.001), 9.31±2.43 days/month in the second month (p<0.001), and increased to 11.97±3.27 days/month in the third month (p<0.001). The mean analgesic intake before BoNTA was 11.48±4.68 tablets/month, while it decreased to 6.53±2.72 tablets/month in the first month (p<0.001) and 5.40±2.46 tablets/month in the second month (p<0.001). In the third month, it was 5.85±2.59 tablets/month (p<0.001). There was a significant increase in pain medication use from the second to the third month (p<0.001). Conclusion: In our study, there was a significant reduction in analgesic intake and headache days in the first and second months after BoNTA injection, and an increase was observed in the third month.

Download Full-text

Botulinum toxin type A in the treatment of hemifacial spasm: an 11-year experience

Arquivos de Neuro-Psiquiatria ◽

10.1590/s0004-282x2010000400006 ◽

2010 ◽

Vol 68 (4) ◽

pp. 502-505 ◽

Cited By ~ 14

Author(s):

Egberto Reis Barbosa ◽

Leonel Tadao Takada ◽

Lilian Regina Gonçalves ◽

Rose Mary Paulo do Nascimento Costa ◽

Laura Silveira-Moriyama ◽

...

Keyword(s):

Botulinum Toxin ◽

Hemifacial Spasm ◽

Botulinum Toxin Type A ◽

Type A ◽

Botulinum Toxin Type ◽

School Of Medicine ◽

Long Term Effect ◽

Subjective Judgement ◽

The Mean

In order to evaluate the long-term effect of botulinum toxin type A (BTX) in the treatment of hemifacial spasm (HFS), a retrospective analysis of patients treated at the Movement Disorders Unit of the Division of Neurology, Clinical Hospital, University of São Paulo, School of Medicine from 1993 to 2004 was made. A total of 808 injections with BTX were administered to 54 patients with HFS. The mean duration of improvement per application was 3.46 months and the mean rate of improvement using subjective judgement by the patient was of 83%. Adverse effects, mostly minor, were observed in 64.8% of patients at least once along the period of follow-up and the most frequent of them was orbicularis oris paralysis (38.8%). There was no decrement in response when compared the first and the last injection recorded.

Download Full-text

Complex Incisional Hernia – Easy To Diagnose But What To Do After?

International Journal of Case Reports ◽

10.28933/ijcr-2021-11-1506 ◽

2021 ◽

pp. 254

Author(s):

Keyword(s):

Botulinum Toxin ◽

Abdominal Wall ◽

Rapid Development ◽

Botulinum Toxin Type A ◽

Type A ◽

Botulinum Toxin Type ◽

Fascial Closure ◽

Loss Of Domain ◽

Umbilical Hernia Repair ◽

Preoperative Progressive Pneumoperitoneum

Introduction. Loss of domain represents a defect in abdominal wall or loss of continuity of fascial closure, with more than 20% of the peritoneal cavity content under the skin in a serous sac, where the reconstruction involves additional reconstructive techniques. Clinical Case. A 63-year-old active smoker with multiple comorbidities such as COPD severe form with the need for oxygen at home (may be an absolute contraindication) and surgical history of open umbilical hernia repair with a rapid development of loss of domain hernia (2 weeks after surgery) was prepared preoperatively with Botulinum Toxin type A and Preoperative Progressive Pneumoperitoneum. Discussion. Despite comorbidities, by optimizing the abdominal wall with Botulinum Toxin type A and Preoperative Progressive Pneumoperitoneum with the intraoperative use of the Rives-Stoppa technique or posterior separation of components, Abdominal Wall Strength Score improves significantly in a short time, with quick socio-economic reintegration and low-rate of complications. Conclusions. By preoperative preparation, with augmentation techniques of the abdominal wall, thus, even the barriers given by comorbidities (absolute contraindications) are overcame, with low postoperative risks, offering the patient a normal quality of life.

Download Full-text